Ariceum Therapeutics announces extension of Series A financing for radiopharmaceutical clinical pipeline

April 18, 2023
Sales and Marketing

Private biotech company Ariceum Therapeutics has announced the successful completion of Series A extension financing, raising an additional €22.75m following …

yunus-tug-lnfgdbcajxu-unsplash

Gamida Cell’s Omisirge receives FDA approval

April 18, 2023
Research and Development

Cell therapy pioneer Gamida Cell has announced FDA approval of its allogeneic cell therapy, Omisirge (omidubicel-onlv), for use in adult …

nik-shuliahin-bunwp1bl0nc-unsplash

FDA approves expanded indication for AbbVie’s chronic migraine treatment

April 18, 2023
Medical Communications

US-based AbbVie has announced that the FDA has granted approval for the expanded indication of its preventative chronic migraine treatment …

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

April 18, 2023
Business Services

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces …

We need more “trial” and less error – a concerted effort is required to include more people aged over 60 in clinical trials, argues longevity experts

April 18, 2023
Business Services

The Trial and error report, published today, urges regulators, pharmaceutical companies and researchers to prioritise age diversity at all stages …

Cantargia presents new clinical data at AACR 2023 strongly supporting nadunolimab development in pancreatic cancer

April 17, 2023
Business Services

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented updated interim clinical efficacy data including subgroup analyses of first-line pancreatic cancer …

ClinOne Closes Series A Funding Round to Scale its Site and Participant Engagement Platform, Data Driven Insights and Interoperability

April 17, 2023
Business Services

BOSTON AND BOULDER, COLO. (PRWEB) APRIL 13, 2023 – ClinOne, the leading provider of Adaptive Experiences in clinical trials announced …

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favourable Tolerability and Immunogenicity Profile

April 17, 2023
Business Services

OXFORD, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) – Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the …

ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens

April 17, 2023
Business Services

OSAKA, Japan, APRIL 17, 2023 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; …

PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

April 17, 2023
Business Services

CAMBRIDGE, MA, April 17, 2023 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based …

national-cancer-institute-kluafqlacfw-unsplash

Companies showcase innovative biotech at American Association for Cancer Research

April 17, 2023
Medical Communications

Leading companies in the biotechnology sector will showcase their latest innovations at the American Association for Cancer Research (AACR) meeting …

Complement Therapeutics gains €72m in Series A financing for novel therapeutics research

April 17, 2023
Medical Communications

Preclinical stage biotechnology company Complement Therapeutics (CTx) has announced the completion of its Series A financing round, led by Gimv, …

towfiqu-barbhuiya-ssz6x-gao0c-unsplash

GSK announces positive data from phase 3 trial for new UTI antibiotic

April 17, 2023
Research and Development

GSK has shared positive data from its phase 3 trial for gepotidacin as a new oral antibiotic for the treatment …

volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

Merck acquires Prometheus Biosciences, strengthens immunology pipeline

April 17, 2023
Sales and Marketing

Merck (known as MSD outside of the US and Canada) has announced that it, through a subsidiary, has agreed to …

MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults

April 17, 2023
Business Services

Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group …

MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)

April 14, 2023
Business Services

NEW YORK, April 14, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical …

mark-paton-bmzkw_nn0pq-unsplash

Neuromod closes €30m financing for new tinnitus treatment device

April 14, 2023
Sales and Marketing

Irish medical device company Neuromod has announced that it has successfully closed a €30m financing intended to further commercialise Lenire, …

towfiqu-barbhuiya-msqb97guxy0-unsplash

Diabeloop announces collaboration with Novo Nordisk for connected diabetes treatment

April 14, 2023
Research and Development

Automated insulin delivery company Diabeloop has announced its collaboration with global healthcare company Novo Nordisk, with an agreement which covers …

steven-hwg-zbsdrthiim4-unsplash

Merck’s relapsing multiple sclerosis trial put on FDA partial clinical hold over liver injuries

April 14, 2023
Research and Development

Merck has announced that its clinical phase 3 study EVOLUTION has been put on partial clinical hold by the FDA …

The Gateway to Local Adoption Series

Latest content